Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression. According to the National Institute of Health (NIH), transthyretin amyloidosis occurs in one of the 100,000 people in the U.S.
Biopharmaceuticals are more inclined towards finding coronavirus cure due to Covid-19 pandemic. There has been a significant delay in research and development activities in transthyretin stabilizers market. Manufacturing and supply chain activities have been affected due to lockdown implemented in several countries. Reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities.
Transthyretin Stabilizers Market: Drivers and Restraints
Global transthyretin stabilizers market is expected to grow due to the increasing prevalence of transthyretin amyloidosis. Rising African-America population increases the demand for transthyretin stabilizers market. Increased healthcare awareness will contribute towards the growth of transthyretin stabilizers market.
The number of transthyretin stabilizers drug launches will propel the market growth during the forecast period. For instance, in 2019 Pfizer Inc. got approval for its transthyretin stabilizers drugs VYNDAQEL and VYNDAMAX from U.S. Food and Drug Administration.
Increasing healthcare expenditure in developed countries will lead to significant transthyretin stabilizers market growth during the forecast period. Whereas, a stringent regulatory requirement for drug approval can hinder the transthyretin stabilizers market growth. Unavailability of advanced diagnostic technology in developing and under-developed countries can challenge transthyretin stabilizers market growth.
Ask for Table Of Content here @ https://www.persistencemarketresearch.com/toc/31873
Transthyretin Stabilizers Market: Segmentation
Based on drug type |
|
Based on disease |
|
Based on the route of administration |
|
Based on the distribution channel |
|
Transthyretin Stabilizers Market: Overview
Tafamidis hold a major revenue share of transthyretin stabilizers market among the drug types. Transthyretin amyloid cardiomyopathy is expected to dominate the transthyretin stabilizers market during the forecast period with the rise in the African-American population. Transthyretin amyloid polyneuropathy is also expected to have significant growth with increased prevalence cases in transthyretin stabilizers market.
Oral drugs hold a major revenue share of transthyretin stabilizers market with increasing demand. On the other hand, intravenous drugs are expected to observe significant growth rate in the coming decade with the advancement of RNAi therapeutics in transthyretin stabilizers market.
Transthyretin Stabilizers Market: Key Market Participants
Major players in transthyretin stabilizers market include Pfizer Inc., Merck & Co., AstraZeneca Plc., GlaxoSmithKline Plc., Corino Therapeutics Inc., Alnylam Pharmaceuticals, Bellus Health Inc., Ionis Pharmaceuticals, Inc., Proclara Bioscience, Arturus Therapeutics, Prothena Corporation Plc., and others.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/31873
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com